SPRB250117P5000
- 0.00
- 0.000.00%
Spruce Biosciences Newsroom
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Hold Rating
RBC Capital Maintains Spruce Biosciences(SPRB.US) With Hold Rating, Cuts Target Price to $1.5
Oppenheimer Maintains Spruce Biosciences(SPRB.US) With Hold Rating
RBC Cuts Price Target on Spruce Biosciences to $1.50 From $2, Keeps Sector Perform, Speculative Risk
Spruce Biosciences Cut to Perform From Outperform by Oppenheimer
Spruce Biosciences Analyst Ratings
Oppenheimer Initiates Spruce Biosciences(SPRB.US) With Hold Rating
Spruce Biosciences Downgraded to Hold Amid Unmet Clinical Trial Endpoints and Strategic Reevaluation
JMP Securities Maintains Spruce Biosciences(SPRB.US) With Hold Rating
JMP Securities Downgrades Spruce Biosciences(SPRB.US) to Hold Rating
JMP Securities Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $3
Spruce Biosciences Analyst Ratings
RBC Capital Maintains Spruce Biosciences(SPRB.US) With Hold Rating, Maintains Target Price $2
RBC Capital Sticks to Their Hold Rating for Spruce Biosciences (SPRB)
JMP Securities Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $3
JMP Securities Maintains Spruce Biosciences(SPRB.US) With Buy Rating, Maintains Target Price $3
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
Spruce Biosciences Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kronos Bio (KRON), Spruce Biosciences (SPRB) and ScPharmaceuticals (SCPH)
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Hold Rating